219 related articles for article (PubMed ID: 19179295)
21. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
[TBL] [Abstract][Full Text] [Related]
24. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N; Szapary P; Brodmerkel C; Benson J; Plotnick M; Zhou H; Goyal K; Schenkel B; Giles-Komar J; Mascelli MA; Guzzo C
Ann N Y Acad Sci; 2012 Aug; 1263():1-12. PubMed ID: 22823582
[TBL] [Abstract][Full Text] [Related]
25. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial.
Wolf P; Weger W; Legat FJ; Posch-Fabian T; Gruber-Wackernagel A; Inzinger M; Salmhofer W; Hofer A
Br J Dermatol; 2012 Jan; 166(1):147-53. PubMed ID: 21910714
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
[TBL] [Abstract][Full Text] [Related]
27. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials.
Guenther L; Han C; Szapary P; Schenkel B; Poulin Y; Bourcier M; Ortonne JP; Sofen HL
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):851-7. PubMed ID: 21521375
[TBL] [Abstract][Full Text] [Related]
28. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
[TBL] [Abstract][Full Text] [Related]
29. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters.
Reddy M; Torres G; McCormick T; Marano C; Cooper K; Yeilding N; Wang Y; Pendley C; Prabhakar U; Wong J; Davis C; Xu S; Brodmerkel C
J Dermatol; 2010 May; 37(5):413-25. PubMed ID: 20536646
[TBL] [Abstract][Full Text] [Related]
30. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
Reich K; Schenkel B; Zhao N; Szapary P; Augustin M; Bourcier M; Guenther L; Langley RG
J Dermatolog Treat; 2011 Dec; 22(6):337-47. PubMed ID: 21034290
[TBL] [Abstract][Full Text] [Related]
31. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
35. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.
Young L; Czarnecki D
Australas J Dermatol; 2012 Feb; 53(1):57-60. PubMed ID: 22309334
[TBL] [Abstract][Full Text] [Related]
36. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
[TBL] [Abstract][Full Text] [Related]
37. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
38. Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis.
Bruin G; Loesche C; Nyirady J; Sander O
J Clin Pharmacol; 2017 Jul; 57(7):876-885. PubMed ID: 28273356
[TBL] [Abstract][Full Text] [Related]
39. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab for chronic plaque psoriasis.
Bartlett BL; Tyring SK
Lancet; 2008 May; 371(9625):1639-40. PubMed ID: 18486724
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
